E-viri
Recenzirano
Odprti dostop
-
Mirza, Mansoor R.; Chase, Dana M.; Slomovitz, Brian M.; dePont Christensen, René; Novák, Zoltán; Black, Destin; Gilbert, Lucy; Sharma, Sudarshan; Valabrega, Giorgio; Landrum, Lisa M.; Hanker, Lars C.; Stuckey, Ashley; Boere, Ingrid; Gold, Michael A.; Auranen, Annika; Pothuri, Bhavana; Cibula, David; McCourt, Carolyn; Raspagliesi, Francesco; Shahin, Mark S.; Gill, Sarah E.; Monk, Bradley J.; Buscema, Joseph; Herzog, Thomas J.; Copeland, Larry J.; Tian, Min; He, Zangdong; Stevens, Shadi; Zografos, Eleftherios; Coleman, Robert L.; Powell, Matthew A.
The New England journal of medicine, 06/2023, Letnik: 388, Številka: 23Journal Article, Web Resource
A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Patients with mismatch repair–deficient tumors had 2-year progression-free survival of 61.4% with dostarlimab and 15.7% with placebo.
